Hydrochloric Acid
Electron Microscopy Sciences Hydrochloric Acid Solution 0.1N, 1 to 2 100 ML
HCl F.W. 36.46
HCl used to adjust the pH of buffers and fixative solutions.
pH: 1 to 2
Electron Microscopy Sciences Hydrochloric Acid Solution 1.0N, 1 to 2 pH 100 ML
HCl F.W. 36.46
Used to adjust the pH of buffers and fixative solutions.
Med Vet International Tamsulosin Hcl 0.4mg, 100 Caps
VET LICENSE NEEDS TO BE PROVIDED IN 3-4 BUSINESS DAYS OR ORDER WILL BE CANCELLED
TAMSULOSIN HCL 0.4MG, 100 CAPS
Med Vet International Solu-Medrol 500mg 4ml Act-O-Vial
VET LICENSE NEEDS TO BE PROVIDED IN 3-4 BUSINESS DAYS OR ORDER WILL BE CANCELLED
Solu-Medrol 500mg 4ml Act-O-Vial
Inorganic Ventures 1.0M Hydrochloric Acid 500mL
1.0M Hydrochloric Acid | MW: 36.461 | 7647-01-0 | MFCD00011324 | 500mL
ATTENTION: Inorganic Ventures is no longer supplying paper copies of Certificate of Analyses(CoA) and Safety Data Sheets (SDS). Please use this link to download your copies: https://www.inorganicventures.com/coa-sds-search
Medchemexpress LLC ARD-2585 | 2757422-79-8 | 98.2% | 763.28 | 1 MG
ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor. It achieves DC50 values of 0.04-0.1 nM in the VCaP cell line with AR gene amplification and in the LNCaP cell line carrying an AR mutation. ARD-2585 (100 nM) is effective in reducing the AR protein level at the 3 and 24 hour time-points by 78% (p < 0.01) and 60% at the 6 hour time-point (p > 0.05).
- Achieves DC50 values of 0.04-0.1 nM in VCaP and LNCaP cell lines.
- Reduces AR protein level by 78% at 3 and 24 hour time-points (100 nM).
- Exhibits antiproliferative activity against human LNCaP cells (IC50: 16.2 nM).
- Exhibits antiproliferative activity against human VCaP cells (IC50: 1.5 nM).
Medchemexpress LLC ARD-69 | 5MG
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells ARD-69 inhibits AR-regulated gene expression binds to the AR ligand binding domain at one end and binds to VHL at the other end prompting AR to be recruited to the E3 ubiquitin ligase complex triggering proteasome degradation thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA TMPRSS2) ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC)[1][2][3] br/ ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624) a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1 4 -bipiperidine]-1 -carboxylate (HY-W442074) and a VHL-type E3 ubiquitinase ligand (blue part) VH 101 acid (HY-47070) among them the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyn
Medchemexpress LLC ARD-69 1mg | 2316837-10-0 | 1 MG
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells ARD-69 inhibits AR-regulated gene expression binds to the AR ligand binding domain at one end and binds to VHL at the other end prompting AR to be recruited to the E3 ubiquitin ligase complex triggering proteasome degradation thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA TMPRSS2) ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC)[1][2][3] br/ ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624) a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1 4 -bipiperidine]-1 -carboxylate (HY-W442074) and a VHL-type E3 ubiquitinase ligand (blue part) VH 101 acid (HY-47070) among them the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyn